World Diagnostics Inc. Names Three to Board of Advisors; Enlarges Scope of Expertise and Market Development.

Business Editors

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Aug. 2, 2001

World Diagnostics Inc. (OTCBB:WDGI), www.worlddiagnostics.com, a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, today announced the formation of a board of advisors to assist the company in its strategic business and market development.

"WDI is a unique company whose up-and-coming business model makes it among the most promising competitors in its field. Revenues have been growing at about 10 percent per month since January 2001, requiring wider know-how to evaluate the health care complexities of globalization," commented Barry Peters, chairman of WDI. "We have been seeking special expertise to understand the dynamics of these conditions and are very pleased to now have the help of several key advisors.

"Emerging and moderately developed economies all are groping for low cost solutions to identify and contain various diseases, especially for rapid diagnosis of infectious diseases. It has become a large and burgeoning market, especially for sexually transmitted and infectious diseases, which are WDI's core product lines. As we advance, we hope to broaden our advisory board and establish ties with various research groups and international organizations interested in the improving global health concerns through the exchange of information, knowledge and experiences."

Board of Advisors

Reynaldo Dietze -- Dr. Dietze is among the foremost epidemiologists in Brazil and is currently a resident professor in Social Medicine and Epidemiology at Universidade Federal do Espirito Santo, Vitoria, Brazil. He has published extensively on the subject of infectious diseases and social medicine, and he is a leading member of the Brazilian Society of Tropical Diseases; Brazilian Society of Infectious Diseases; American Society of Tropical Medicine and Hygiene; Infectious Diseases Society of America; Royal Society of Tropical Medicine and Hygiene.

Formerly an Associate Professor of Medicine at Duke University Medical Center, Dr. Dietze has been a principal investigator of a large-scale study on the epidemiology of malaria in Brazil in collaboration with The Walter Reed Army Institute of Research, a Research Fellow to Nucleo de Medicina Tropical e Nutricao, and advisor to University of Brasilia on matters of epidemiology.

David M. Sloan -- Sloan is President of Corporate Strategies International, a consultancy that assists companies to identify entry strategies and joint venture partners with regard to market access and research concerning political, economic and commercial matters. Sloan also is an advisor with the Scowcroft Group, and previously was affiliated with Charles Percy & Associates, a Washington-based international relations and trade consulting firm, headed by former Senator Charles Percy.

Sloan spent eight years as an Economic Officer for the U.S. Department of State, and was a Special Assistant to the Under Secretary of State for Economic Affairs, assigned to the National Security Council at the White House. His articles on international affairs have appeared in the New York Times, Los Angeles Times, Asian Wall Street Journal, International Herald Tribune, Christian Science Monitor, Journal of Commerce, Business India and The Observer of Business and Politics.

Charles Galanaugh -- Galanaugh's career spans 35 years of managerial roles, including product development, engineering, marketing and sales, and corporate business development in the clinical laboratory (in vitro diagnostic) industry with Becton Dickinson and Co. Most recently, he was Editor of The Genesis Report / Dx, an industry-focused newsletter, and a senior consultant for The Genesis Group, which deals with strategic implications of technology innovation in diagnostic medicine. He also served as President of the NCCLS, the global organization for clinical laboratory practice standards.

He currently serves on the board of trustees of the Van Slyke Society, an affiliate of the American Association for Clinical Chemistry that supports programs in education, research and career development. He has been a speaker and author for conferences and publications throughout the world, especially with respect to application of technology innovations in diagnostic information, pharmacogenomics and health care automation.

About WDI/GLOBALeMED.com

WDI is an innovative leader for providing a wide range of medical diagnostic and laboratory products worldwide, offering a simplified option, through its GLOBALeMED system, for purchasing medical laboratory and health care products, and for professionals to access critical technical data and information, training aids and online customer support.

WDI's network of distributors and GLOBALeMED partners now covers 80 countries, offering the most comprehensive resource for most medical diagnostic tests and laboratory products, currently comprised of about 1,000 WDI branded products, and numerous other products, that are sold through distributors and directly to medical professionals, hospitals, physician offices, clinical laboratories and retail drug stores.

WDI's vision is to become the premier resource for supplying diagnostic tests and allied medical laboratory products for the $5.0 billion emerging nation global marketplace. WDI is aggressively expanding its business and brand name through its distribution network and its GLOBALeMED e-commerce platform, which can be accessed at either www.worlddiagnostics.com or www.globalemed.com.

Except for historical matters contained herein, the matters discussed in this news release are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the assumptions and involve risk and uncertainties, which may affect World Diagnostics Inc.'s business and prospects and cause actual results to differ materially from these forward-looking statements.